Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) Tax Provisions (2020 - 2025)

Historic Tax Provisions for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Q3 2025 value amounting to -$262000.0.

  • Mirum Pharmaceuticals' Tax Provisions fell 17550.43% to -$262000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $593000.0, marking a year-over-year decrease of 6761.33%. This contributed to the annual value of $1.0 million for FY2024, which is 393.54% up from last year.
  • According to the latest figures from Q3 2025, Mirum Pharmaceuticals' Tax Provisions is -$262000.0, which was down 17550.43% from $402000.0 recorded in Q2 2025.
  • In the past 5 years, Mirum Pharmaceuticals' Tax Provisions ranged from a high of $1.0 million in Q1 2025 and a low of -$6.6 million during Q2 2022
  • Moreover, its 5-year median value for Tax Provisions was $140000.0 (2022), whereas its average is -$167315.8.
  • In the last 5 years, Mirum Pharmaceuticals' Tax Provisions crashed by 5982727.27% in 2022 and then soared by 181538.46% in 2023.
  • Quarter analysis of 5 years shows Mirum Pharmaceuticals' Tax Provisions stood at $12000.0 in 2021, then soared by 1066.67% to $140000.0 in 2022, then surged by 60.71% to $225000.0 in 2023, then crashed by 356.0% to -$576000.0 in 2024, then soared by 54.51% to -$262000.0 in 2025.
  • Its Tax Provisions stands at -$262000.0 for Q3 2025, versus $402000.0 for Q2 2025 and $1.0 million for Q1 2025.